BioLife Solutions First Quarter 2025 Earnings: Beats Expectations

BioLife Solutions (NASDAQ:BLFS) First Quarter 2025 Results

Key Financial Results

• Revenue: US$23.9m (down 11% from 1Q 2024).
• Net loss: US$448.0k (loss narrowed by 89% from 1Q 2024).
• US$0.01 loss per share (improved from US$0.093 loss in 1Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

BioLife Solutions Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 7.7%. Earnings per share (EPS) also surpassed analyst estimates by 81%.

Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 7.8% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on BioLife Solutions' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.